论文部分内容阅读
目的:探讨雷贝拉唑辅助治疗胃溃疡患者的临床效果及安全性。方法:2014年2月到2016年12月选择我院消化内科的胃溃疡患者80例作为研究对象,按照随机自愿的原则分为观察组与对照组各40例,对照组给予常规三联疗法治疗,观察组在对照组治疗的基础上给予雷贝拉唑辅助治疗,两组治疗疗程都为4周。结果:治疗后观察组与对照组的总有效率分别为97.5%和87.5%,观察组的总有效率明显高于对照组(P<0.05),两组在治疗期间都无严重不良反应情况发生。治疗后观察组的Hp根除率明显高于对照组(P<0.05)。结论:雷贝拉唑辅助治疗胃溃疡患者能改善临床症状,安全性比较好,促进根除幽门螺旋杆菌,提高治疗效果,有很好的应用价值。
Objective: To investigate the clinical effect and safety of rabeprazole in the treatment of patients with gastric ulcer. Methods: From February 2014 to December 2016, 80 patients with gastric ulcer who selected our department of gastroenterology were divided into observation group (40 cases) and control group (40 cases) according to the principle of random and voluntary. The control group was given conventional triple therapy, The observation group received adjunctive treatment with rabeprazole on the basis of the treatment of the control group, and both treatment courses were 4 weeks. Results: The total effective rate of observation group and control group after treatment was 97.5% and 87.5%, respectively, and the total effective rate in observation group was significantly higher than that in control group (P <0.05). No serious adverse reactions occurred in both groups during treatment . Hp eradication rate in the observation group after treatment was significantly higher than that in the control group (P <0.05). Conclusion: Rabeprazole adjuvant treatment of gastric ulcer patients can improve clinical symptoms, safety is better, promote the eradication of Helicobacter pylori, improve the therapeutic effect, has a very good value.